2012 Fiscal Year Final Research Report
Therapeutic Strategy of Diabetic Macroangiopathy using the Gut Hormone Incretin
| Project/Area Number |
22590831
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Circulatory organs internal medicine
|
|---|
| Research Institution | Tokyo University of Pharmacy and Life Science |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HIRANO Tsutomu 昭和大学, 医学部, 教授 (00167610)
KOBA Shinji 昭和大学, 医学部, 講師 (20276546)
NAGASHIMA Masaharu 昭和大学, 医学部, 助教 (20468606)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Keywords | 分子血管病態学 |
|---|
| Research Abstract |
The present study shows that incretin-based therapy using DPP-4 inhibitors and GLP-1 analogs, new treatment of diabetes, exerts anti-atherosclerotic effects, other than glucose lowering effect, leading to the prevention of diabetic macroangiopahy (coronary arterydisease, cerebrovascular disease, and arteriosclerosis obliterans). The pleiotrophic effects are attributed to anti-atherogenesis of GLP-1 and/or GIP on vascular cells, such as endothelial cells, vascular smooth muscle cells, and monocytes/macrophages, via individual receptors followed by cAMP activation.
|
